Immutep (IMMP) and Pluristem Therapeutics (PSTI) Head-To-Head Comparison
Immutep (NASDAQ: IMMP) and Pluristem Therapeutics (NASDAQ:PSTI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.
Insider and Institutional Ownership
0.4% of Immutep shares are held by institutional investors. Comparatively, 4.3% of Pluristem Therapeutics shares are held by institutional investors. 7.0% of Pluristem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Immutep and Pluristem Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Immutep has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Pluristem Therapeutics has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for Immutep and Pluristem Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Immutep presently has a consensus price target of $7.00, suggesting a potential upside of 268.44%. Pluristem Therapeutics has a consensus price target of $3.83, suggesting a potential upside of 138.10%. Given Immutep’s higher possible upside, research analysts clearly believe Immutep is more favorable than Pluristem Therapeutics.
Earnings and Valuation
This table compares Immutep and Pluristem Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Immutep||$3.18 million||14.00||-$7.06 million||N/A||N/A|
|Pluristem Therapeutics||$2.85 million||61.07||-$27.81 million||($0.32)||-5.03|
Immutep has higher revenue and earnings than Pluristem Therapeutics.
Immutep beats Pluristem Therapeutics on 6 of the 9 factors compared between the two stocks.
Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.
Receive News & Ratings for Immutep Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep and related companies with Analyst Ratings Network's FREE daily email newsletter.